The development programs of the company include radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products for treatment of various solid cancers. The companys’s lead candiate Radspherin is currently developed for two indications, peritoneal carcinomatosis from ovarian cancer and from colorectal cancer, but are also relevant for treating other types of cancers.